RG
SRNE

Rathbones Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Rathbones Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,784
Closed -$395K – 439
2021
Q2 		$395K Sell
40,784
-1,700
-4% -$13.5K ﹤0.01% 332
2021
Q1 		$351K Hold
42,484
– – ﹤0.01% 326
2020
Q4 		$290K Hold
42,484
– – ﹤0.01% 334
2020
Q3 		$474K Sell
42,484
-3,000
-7% -$27.5K 0.01% 265
2020
Q2 		$286K Sell
45,484
-1,300
-3% -$4.98K 0.01% 296
2020
Q1 		$86K Sell
46,784
-15,000
-24% -$43.2K ﹤0.01% 303
2019
Q4 		$209K Hold
61,784
– – 0.01% 305
2019
Q3 		$132K Buy
+61,784
New +$144K ﹤0.01% 309

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rathbones Group's SRNE Position: Q3 2021 in Review

Rathbones Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2021, closing a stake of 40,784 shares — an estimated $395K sold.

Rathbones Group first reported a position in SRNE in Q3 2019 and held it in 8 quarters. The position peaked at $474K in Q3 2020. 220 funds tracked by Wall St. Rank hold SRNE as of Q3 2021.

  • Rathbones Group reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Rathbones Group sold 40,784 Sorrento Therapeutics, Inc. shares in Q3 2021, an estimated $395K.
  • Rathbones Group first reported a position in Sorrento Therapeutics, Inc. in Q3 2019 and held it in 8 quarters.
  • Rathbones Group's Sorrento Therapeutics, Inc. position peaked at $474K in Q3 2020.
  • 220 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2021.

Based on Rathbones Group's 13F filing for Q3 2021, filed 4 Nov 2021.